U.S. Application No. 10/018,964 Confirmation No. 6025 Amendment dated January 18, 2006

## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

## Listing of Claims

1. (Currently Amended) An isolated peptide comprising:

Tyr-Ser Gly Pro-Pro Xan, Xan, Xan, Arg Arg Arg Xan, Asn Xan, Tyr Xan, (SEQ ID NO: 1)
wherein Xan, Cys or Ser; Xan, Ser or Gly, Xan, Ser, Ala or Pro; Xan, Arg or Gln; Xan,
Ser, Cys or Gly; and Xan, Asp or Glu
Tyr-Ser-Gly-Pro-Pro-Ser-Gly-Ala-Arg-Arg-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1);

wherein the isolated peptide does not include a <u>basic helix-loop-helix (bHLH)</u> domain; wherein the isolated peptide binds cyclin dependent kinase 4.

- 2. (Canceled)
- (Currently Amended) A fusion protein comprising:
  - (a) a peptide comprising Tyr-Ser Gly-Pro-Pro-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Aa<sub>2</sub>-Arg-Arg-Xaa<sub>4</sub>-Asn-Xaa<sub>5</sub>-Tyr-Xaa<sub>6</sub> (SEQ ID NO: 1) wherein Xaa<sub>4</sub>= Cys or Ser; Xaa<sub>2</sub>= Ser or Gly; Xaa<sub>3</sub>= Ser; Ala or Pro; Xaa<sub>4</sub>= Arg or Gln; Xaa<sub>5</sub>= Ser, Cys or Gly; and Xaa<sub>6</sub>=Asp or Glu Tyr-Ser-Gly-Pro-Pro-Ser-Gly-Ala-Arg-Arg-Arg-Asn-Cys-Tyr-Glu (SEQ ID NO:1), wherein the peptide binds cyclin dependent kinase 4; and
  - (b) a heterologous amino acid sequence.
- 4. (Original) The fusion protein of claim 3 wherein the heterologous amino acid sequence comprises a nuclear localization signal.
- 5. (Previously Presented) The fusion protein of claim 4 wherein the peptide is at the C-terminus of the fusion protein.
- 6-7. (Canceled)

U.S. Application No. 10/018,964 Confirmation No. 6025 Amendment dated January 18, 2006

8. (Withdrawn and Currently Amended) A method of inhibiting cell growth, comprising: administering to a patient a CDK4 binding peptide comprising:

Tyr Ser-Gly Pro-Pro-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Arg Xaa<sub>3</sub>-Arg Xaa<sub>4</sub>-Asn Xaa<sub>5</sub>-Tyr-Xaa<sub>6</sub>
whereir Xaa<sub>1</sub>= Cys or Ser: Xaa<sub>2</sub>= Ser or Gly; Xaa<sub>3</sub>= Ser, Ala or Pro; Xaa<sub>4</sub>=Arg or Gln; Xaa<sub>5</sub>=
Ser, Cys or Gly; and Xaa<sub>6</sub>:=Asp or Glu Tyr-Ser-Gly-Pro-Ser-Gly-Ala-Arg-Arg-Asn-Cys-Tyr-Glu
(SEO 1D NO:1), wherein the peptide does not include a basic helix-loop-helix domain in an amount effective to inhibit cell growth.

9. (Withdrawn and Currently Amended) A method of inhibiting the activity of CDK4 comprising:

contacting CDK4 with a CDK4 binding peptide comprising:

Tyr-Ser-Gly Pro-Pro-Xan<sub>1</sub>-Xan<sub>2</sub>-Xan<sub>3</sub>-Arg Arg Xan<sub>4</sub>-Asn-Xan<sub>5</sub>-Tyr-Xan<sub>6</sub>

wherein Xan<sub>4</sub>- Cys or Ser; Xan<sub>2</sub>-Ser or Gly; Xan<sub>3</sub>- Ser, Ala or Pro; Xan<sub>4</sub>-Arg or Gln; Xan<sub>5</sub>
Ser, Cys or Gly; and Xan<sub>6</sub>-Asp or Glu Tyr-Ser-Gly-Pro-Ser-Gly-Ala-Arg-Arg-Asn-Cys-Tyr-Glu

(SEO ID NO:1), wherein the peptide does not include a basic helix-loop-helix domain in an amount effective to inhibit the activity of CDK4.

10-11. Cancelled.